Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining ...

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that ...

California Democratic Rep. Jared Huffman protested the National Prayer Breakfast Thursday, claiming it violates the ...

(KOA), the largest system of privately owned campgrounds in the world, is proud to announce that Mt. Gilead KOA Holiday has ...

As a KOA ICON campground, Mt. Gilead KOA Holiday will enjoy unique benefits designed to amplify their achievement, including dated logo placement on KOA.com, enhanced award designation marketing ...

TD Cowen raised the firm’s price target on Gilead (GILD) to $100 from $95 and keeps a Buy rating on the shares. The firm said they posted a ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

Cognizant (NASDAQ: CTSH) has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences (NASDAQ: GILD) that aims to unlock even greater value for Gilead as ...

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...